Aurora Cannabis Denies Report of $215M MedLeaf Acquisition

*EDMONTON, Canada* – Aurora Cannabis Inc. (NASDAQ: ACB) issued a formal
denial Wednesday regarding widely circulated reports claiming the company
planned to acquire New Zealand–based MedLeaf Therapeutics in a $215-million
cash-and-stock transaction. The denial, published via PR Newswire,
clarified that no such deal has been made or is under consideration.

The initial report, published by Investing.com and echoed by a
cannabis-industry trade journal and several financial media outlets,
alleged Aurora announced an acquisition worth more than $125 million in
cash and $90 million in stock, with the transaction slated to close by
August 31. The supposed strategic goal: to expand Aurora’s footprint in the
European and Australian medical cannabis markets.

According to Investing.com, its report was “based on an SEC filing
submitted by Aurora Cannabis Inc.” and generated by artificial intelligence
with an editor’s review.

In stark contrast to what the AI-generated report indicated, Aurora’s
official response stated the company “has not entered into any such
agreement, has had no discussions with MedLeaf Therapeutics with respect to
any business combination transaction, and has not made any statement or
filed any information pertaining to any such transaction.”

The press release further clarified that financial reports filed via EDGAR
and SEDAR before the markets opened on June 18 were related solely to the
company’s performance during the fourth-quarter and fiscal year ended March
31, 2025.